logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Cancer and Palliative Care

Results

Drugs

October 2021

Elranatamab for treating relapsed /refractory multiple myeloma

Elranatamab is in clinical development for relapsed/refractory multiple myeloma (MM). MM is a rare, incurable cancer of the blood that develops from plasma cells in the bone marrow (the spongy tissue inside the inner part of some bones) where large amounts of abnormal plasma cells are produced and interfere with the production of red and …

Drugs

October 2021

Pralsetinib for treating thyroid cancer

Pralsetinib is in clinical development for the treatment of thyroid cancer. Thyroid cancer is a rare type of cancer that affects the thyroid gland, a small gland at the base of the neck that produces hormones. Thyroid cancer can happen when there are genetic changes in the thyroid cells, which cause them to grow uncontrollably …

Drugs

October 2021

Tislelizumab for advanced non-small cell lung cancer after platinum based chemotherapy

Tislelizumab is in clinical development to treat patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have previously been treated with platinum-based chemotherapy. NSCLC makes up the majority of lung cancers in the UK. Metastatic NSCLC is when the cancer has spread beyond the lung that was initially affected, most often to …

Drugs

October 2021

Durvalumab in addition to gemcitabine and cisplatin for advanced biliary tract cancer – first line

Durvalumab in combination with gemcitabine plus cisplatin is being developed for patients with advanced biliary tract cancer (BTC). BTC is a rare type of cancer that affects bile ducts, which are tubes that link the gallbladder, liver and pancreas together. Bile is produced in the gallbladder and is transported to the small intestine to aid …

Drugs

October 2021

Pembrolizumab in combination with olaparib as maintenance therapy for non-small-cell lung cancer following first line treatment

Pembrolizumab in combination with olaparib is currently in development as a maintenance treatment of non-small cell lung cancer (NSCLC) in those that have not progressed following first line treatment. NSCLC makes up the majority of lung cancers in the UK and most patients are diagnosed at the advanced/metastatic stage where curative treatment with surgery is …

Drugs

October 2021

Tislelizumab in combination with chemotherapy for nasopharyngeal cancer – first line

Tislelizumab in combination with gemcitabine and cisplatin is in clinical development for the treatment of patients with recurrent or metastatic nasopharyngeal cancer (NPC). NPC is a rare type of cancer that affects the part of the throat connecting the back of the nose to the back of the mouth (the pharynx). It is often difficult …

Drugs

October 2021

Sacituzumab govitecan for treating HR+/HER2- negative metastatic breast cancer

Sacituzumab govitecan is in clinical development for the treatment of adult patients with hormone receptor positive and human epidermal growth factor 2 negative (HR+/HER2-) metastatic breast cancer, whose disease has progressed despite treatment with at least two prior rounds of chemotherapy. Survival outcomes for patients with metastatic breast cancer are poor and current chemotherapy options …

Drugs

October 2021

Pembrolizumab for treatment of solid tumours – second line

Pembrolizumab is currently in clinical development for unresectable or metastatic microsatellite instability high (MSI-H) or deficient mismatch repair (dMMR) endometrial, gastric, biliary, small intestine, or pancreatic cancer in adult patients. MSH-H or dMMR cancers occur when the process for replicating and repairing DNA (genetic material) is not working properly. When a cells misatch repair system …

Drugs

October 2021

Pembrolizumab plus chemotherapy for the treatment of gastric cancer or gastro-oesophageal junction cancer – First Line

Pembrolizumab in addition to chemotherapy is being developed as first-line treatment of HER2 negative advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma in adults. Cancers of the stomach (gastric cancers) and at the intersection of the stomach and the oesophagus (gastroesophageal cancers) often start in the gland cells – these cancers are called adenocarcinomas. As the …

Drugs

September 2021

Ciltacabtagene autoleucel for relapsed and refractory multiple myeloma

Ciltacabtagene autoleucel is in clinical development for the treatment of adults with relapsed and lenalidomide-refractory multiple myeloma (MM). MM is a rare, incurable cancer of the plasma cells in the bone marrow. Abnormal plasma cells interfere with the production of red and white blood cells as well as platelets, causing symptoms such as bone pain …

Get Alerts